{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:52:05Z","timestamp":1772110325735,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejca.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T17:53:05Z","timestamp":1523123585000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"97","author":[{"given":"Constance","family":"Thibault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Baciarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvestre","family":"Le Moulec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Spaeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Laurent","family":"Deville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillipe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hasbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostefa","family":"Bennamoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2012.09.005","article-title":"Progress in emerging therapies for advanced prostate cancer","volume":"39","author":"Oudard","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl_6","key":"10.1016\/j.ejca.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/annonc\/mdw372.28","article-title":"Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men eith metastatic castration-resistance prostate cancer in real life practice: the multinational, retrospective, observational CATS study","volume":"27","author":"Angelergues","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.critrevonc.2015.07.013","article-title":"Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"96","author":"Maines","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2018.03.008_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.03.008_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14656566.2015.995090","article-title":"Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejca.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/pros.22872","article-title":"A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer","volume":"74","author":"Azad","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post Hoc Analysis of COU-AA-302","volume":"71","author":"de Bono","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","article-title":"The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer","volume":"66","author":"Schweizer","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bju.12845","article-title":"Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer","volume":"115","author":"Oudard","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"e2299","DOI":"10.1097\/MD.0000000000002299","article-title":"Lack of cumulative toxicity associated with cabazitaxel Use in prostate cancer","volume":"95","author":"Di Lorenzo","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eururo.2013.10.037","article-title":"Poor survival in prostate cancer patients with primary refractoriness to docetaxel","volume":"65","author":"Di Lorenzo","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers in\u00a0vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer","volume":"67","author":"van Soest","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.03.008_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression\u2013implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.urology.2011.11.043","article-title":"Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors","volume":"79","author":"Caffo","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ejca.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1464-410X.2010.09498.x","article-title":"Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer","volume":"107","author":"Di Lorenzo","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-410X.2010.09296.x","article-title":"Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study","volume":"106","author":"Eymard","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"e2754","DOI":"10.1097\/MD.0000000000002754","article-title":"Docetaxel rechallenge in a heavily pretreated patient with castration-resistant prostate cancer: a case report and review of literature","volume":"95","author":"Di Lorenzo","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clgc.2012.01.011","article-title":"Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report","volume":"10","author":"Perry","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.ejca.2015.07.037","article-title":"The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer","volume":"51","author":"van Soest","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/pros.23182","article-title":"Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation","volume":"76","author":"de Morree","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2018.03.008_bib24","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.008_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.03.008_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.03.008_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7150\/jca.17644","article-title":"Efficacy of cabazitaxel treatment in metastatic castration resistant prostate cancer in second and later lines. An experience from two German centers","volume":"8","author":"Zschabitz","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2018.03.008_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1684\/bdc.2012.1608","article-title":"Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France","volume":"99","author":"Pouessel","year":"2012","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.008_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bju.13855","article-title":"Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer","volume":"121","author":"Clement-Zhao","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.03.008_bib30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.ejca.2010.04.010","article-title":"The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer","volume":"46","author":"Loriot","year":"2010","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T14:10:17Z","timestamp":1571062217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918307251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"alternative-id":["S0959804918307251"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}